Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis
Article 2023 en
Authors
AA
Ali Al‐Janabi
OA
Oras Alabas
ZY
Zenas Z N Yiu
Abstract
1 min read
In this study, in biologic-treated patients with psoriasis, paradoxical eczema risk was lowest in patients receiving IL-23 inhibitors. Increasing age, female sex, and history of AD or hay fever were associated with higher risk of paradoxical eczema. The overall incidence of paradoxical eczema was low. Further study is needed to replicate these findings.
Ali Al‐Janabi, Stephen Eyre, Amy Foulkes, Adnan R. Khan, Nick Dand, Ekaterina Burova, Bernadette DeSilva, Areti Makrygeorgou, Emily Davies, Catherine Smith, Christopher Em Griffiths, Andrew P. Morris, Richard B. Warren
Ali Al‐Janabi, Paul Martin, Adnan R. Khan, Amy Foulkes, Catherine Smith, Christopher Em Griffiths, Andrew P. Morris, Stephen Eyre, Richard B. Warren, Shehnaz Ahmed, Oras Alabas, Juliet N. Barker, G Becher, Anthony Bewley, Ian M. Evans, Philip Hampton, Brian Kirby, Elise Kleyn, Philip Laws, Linda Lawson, Teena Mackenzie, Kathleen McElhone, Tess McPherson,
Claire M. Vajdic, Michael O. Falster, Sílvia de Sanjosé, Otoniel Martı́nez-Maza, Nikolaus Becker, Paige M. Bracci, Mads Melbye, Karin E. Smedby, Eric A. Engels, Jennifer Turner, Paolo Vineis, Adele Seniori Costantini, Elizabeth A. Holly, Eleanor Kane, John J. Spinelli, Carlo La Vecchia, Tongzhang Zheng, Brian C.‐H. Chiu, Luigino Dal Maso, Pierluigi Cocco, Marc Maynadié, Lenka Foretová, Anthony Staines, Paul Brennan,
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.